EP0651634A1 - Cross-linked polyhydroxylic material for enzymatically controlled drug release. - Google Patents

Cross-linked polyhydroxylic material for enzymatically controlled drug release.

Info

Publication number
EP0651634A1
EP0651634A1 EP93915611A EP93915611A EP0651634A1 EP 0651634 A1 EP0651634 A1 EP 0651634A1 EP 93915611 A EP93915611 A EP 93915611A EP 93915611 A EP93915611 A EP 93915611A EP 0651634 A1 EP0651634 A1 EP 0651634A1
Authority
EP
European Patent Office
Prior art keywords
cross
amylase
alpha
linked
drug release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93915611A
Other languages
German (de)
French (fr)
Other versions
EP0651634B1 (en
Inventor
Mircea A Mateescu
Yves Dumoulin
Louis Cartilier
Vincent Lenaerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labopharm Inc
Original Assignee
Labopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc filed Critical Labopharm Inc
Publication of EP0651634A1 publication Critical patent/EP0651634A1/en
Application granted granted Critical
Publication of EP0651634B1 publication Critical patent/EP0651634B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, (alpha)-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the (alpha)-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of (alpha)-amylase in the tablet. The amount of (alpha)-amylase is defined in terms of Enzyme Units.
EP93915611A 1992-07-24 1993-07-22 Cross-linked polyhydroxylic material for enzymatically controlled drug release Expired - Lifetime EP0651634B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91976292A 1992-07-24 1992-07-24
US919762 1992-07-24
PCT/CA1993/000298 WO1994002121A1 (en) 1992-07-24 1993-07-22 Cross-linked polyhydroxylic material for enzymatically controlled drug release

Publications (2)

Publication Number Publication Date
EP0651634A1 true EP0651634A1 (en) 1995-05-10
EP0651634B1 EP0651634B1 (en) 1996-05-08

Family

ID=25442612

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915611A Expired - Lifetime EP0651634B1 (en) 1992-07-24 1993-07-22 Cross-linked polyhydroxylic material for enzymatically controlled drug release

Country Status (18)

Country Link
EP (1) EP0651634B1 (en)
JP (1) JP3647859B2 (en)
KR (1) KR100304997B1 (en)
AT (1) ATE137668T1 (en)
AU (1) AU668198B2 (en)
CA (1) CA2140032C (en)
CZ (1) CZ283395B6 (en)
DE (1) DE69302580T2 (en)
ES (1) ES2086949T3 (en)
FI (1) FI950301A0 (en)
GR (1) GR3020476T3 (en)
HU (1) HU221591B (en)
MX (1) MX9304459A (en)
NO (1) NO308024B1 (en)
NZ (1) NZ254048A (en)
PL (1) PL173249B1 (en)
RU (1) RU2136270C1 (en)
WO (1) WO1994002121A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173818A1 (en) * 1996-04-10 1997-10-11 Francois Chouinard Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose
DE19640062B4 (en) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Oral preparation comprising in a matrix swellable in an aqueous medium at least one pharmaceutical active substance
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US6077537A (en) * 1997-05-21 2000-06-20 Warner-Lambert Company Non-sedating acrivastine product
US5989589A (en) * 1997-10-24 1999-11-23 Cartilier; Louis Cross-linked cellulose as a tablet excipient
US6660303B2 (en) 1999-12-06 2003-12-09 Edward Mendell & Co. Pharmaceutical superdisintegrant
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
JP5269595B2 (en) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー Trazodone composition for once daily administration
EP1946780B1 (en) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
BR112013000190A2 (en) 2010-07-06 2017-11-07 Gruenenthal Gmbh gastric retention dosage forms comprising a gaba analogue and an opioid
AR082167A1 (en) 2010-07-14 2012-11-14 Gruenenthal Gmbh GASTRORTENTIVE DOSAGE FORMS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3181998A (en) * 1960-08-12 1965-05-04 Joseph L Kanig Tablet disintegration
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
SE420565B (en) * 1974-06-06 1981-10-19 Pharmacia Ab AID FOR INTRAVASCULAR ADMINISTRATION FOR USE IN CONNECTION WITH INTRAVASCULAR ADMINISTRATION OF A SOLUTION OR SUSPENSION OF A DIAGNOSTIC AGENT
DE3721574A1 (en) * 1987-06-30 1989-01-12 Kettelhack Riker Pharma Gmbh MEDICINAL PRODUCTS IN THE FORM OF PELLETS WITH ENZYMATICALLY CONTROLLED DRUG RELEASE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9402121A1 *

Also Published As

Publication number Publication date
CA2140032C (en) 1999-01-26
CA2140032A1 (en) 1994-02-03
FI950301A (en) 1995-01-24
DE69302580T2 (en) 1996-09-26
GR3020476T3 (en) 1996-10-31
NO308024B1 (en) 2000-07-10
CZ15295A3 (en) 1995-09-13
HUT75673A (en) 1997-05-28
PL307234A1 (en) 1995-05-15
AU668198B2 (en) 1996-04-26
RU2136270C1 (en) 1999-09-10
NO950251D0 (en) 1995-01-23
EP0651634B1 (en) 1996-05-08
JPH08502036A (en) 1996-03-05
KR100304997B1 (en) 2002-04-24
JP3647859B2 (en) 2005-05-18
PL173249B1 (en) 1998-02-27
HU9500197D0 (en) 1995-03-28
FI950301A0 (en) 1995-01-24
NZ254048A (en) 1995-09-26
DE69302580D1 (en) 1996-06-13
HU221591B (en) 2002-11-28
WO1994002121A1 (en) 1994-02-03
MX9304459A (en) 1994-04-29
AU4555993A (en) 1994-02-14
ES2086949T3 (en) 1996-07-01
ATE137668T1 (en) 1996-05-15
CZ283395B6 (en) 1998-04-15
NO950251L (en) 1995-01-23

Similar Documents

Publication Publication Date Title
HU9500197D0 (en) Gross-linked polyhydroxylic material for enzymatically controlled drug release
ZA973054B (en) Pharmaceutical controlled released tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose.
FI954232A0 (en) Crosslinked amylose as a binder / antibonding agent in tablets
ES2162922T3 (en) COMPOSITION FOR COLONIC ADMINISTRATION OF MEDICINES.
PL321898A1 (en) Application of inorganic aerogles in pharmaceutics
NO20001042D0 (en) Ophthalmic delayed release preparations containing water-soluble drugs
AR002019A1 (en) A SUGAR COATING COMPOSITION FOR APPLICATION TO A COMPRESSED MEDICINAL TABLET AND A COMPRESSED TABLET.
NO813826L (en) Pain-degrading drug presses
ATE187640T1 (en) MEDICINAL PRODUCT IN TABLET FORM WITH DELAYED RELEASE BASED ON HIGH MOLECULAR POLYSACCHARIDE GRANULES
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
DE59504270D1 (en) RETARD TABLET WITH A CONTENT OF DICLOFENAC-NA
DE69225053D1 (en) COMPOSITIONS BASED ON COLLAGES FOR CONTROLLED RELEASE OF MEDICINAL PRODUCTS
DE59607949D1 (en) SOLID MEDICINAL FORM WITH POLYMER MATERIAL DISTRIBUTED ACTIVE SUBSTANCE
HUP9902681A2 (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydroxypropylmethylcellulose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950905

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Effective date: 19960508

Ref country code: BE

Effective date: 19960508

Ref country code: AT

Effective date: 19960508

REF Corresponds to:

Ref document number: 137668

Country of ref document: AT

Date of ref document: 19960515

Kind code of ref document: T

ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 68304

REF Corresponds to:

Ref document number: 69302580

Country of ref document: DE

Date of ref document: 19960613

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2086949

Country of ref document: ES

Kind code of ref document: T3

ITF It: translation for a ep patent filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Effective date: 19960808

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3020476

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Effective date: 19970131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20120626

Year of fee payment: 20

Ref country code: IE

Payment date: 20120626

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20120625

Year of fee payment: 20

Ref country code: SE

Payment date: 20120626

Year of fee payment: 20

Ref country code: GB

Payment date: 20120629

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120625

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120625

Year of fee payment: 20

Ref country code: FR

Payment date: 20120806

Year of fee payment: 20

Ref country code: ES

Payment date: 20120716

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20120621

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69302580

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69302580

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20130722

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130721

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 960401844

Country of ref document: GR

Effective date: 20130723

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130723

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130721

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130722